FITC anti-human CD90 (Thy1) Antibody

Pricing & Availability
Clone
5E10 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
Thy-1, Thy1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
5E10_FITC_020708
Human erythroleukemic cell line (HEL) stained with 5E10 FITC
  • 5E10_FITC_020708
    Human erythroleukemic cell line (HEL) stained with 5E10 FITC
Compare all formats See FITC spectral data
Cat # Size Price Quantity Check Availability Save
328107 25 tests 81€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
328108 100 tests 184€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD90 is a 25-35 kD GPI-anchored protein, also known as Thy-1. It belongs to the Ig superfamily. Human CD90 is expressed on neuronal cells, a subset of CD34+ cells, a subset of fetal liver cells and fetal thymocytes, fibroblasts, activated endothelial cells, and some leukemia cell lines. CD34+CD90+ cells are primitive hematopoietic stem cells. It has been reported that Thy-1 binds with β2 and β3 integrins and plays bimodal roles in the regulation of cell adhesion and neurite outgrowth, and inhibits hematopoietic stem cells proliferation and differentiation.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Pigtailed Macaque, Rhesus, Pig
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
HEL cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone 5E10 recognizes an epitope on Thy-1 independent of its glycosylation, but is abolished under reducing conditions.4 Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation1, and immunofluorescence3.

Application References

(PubMed link indicates BioLegend citation)
  1. Craig W, et al. 1993. J. Exp. Med. 177:1331. (IP)
  2. Gundlach CW 4th, et al. 2011. Bioconjug. Chem. 22:1706. (Pig Reactivity)
  3. Touboul C, et al. 2013. J. Transl. Med. 11:28. (IF)
  4. Bradley JE, et al. 2013. Lab Invest. 93:365. (Epitope)
  5. Donnenberg VS, et al. 2010. Cytometry B. Clin. Cytom. 5:287. (IHC)
Product Citations
  1. Miksiunas R, et al. 2021. Int J Mol Sci. 22:. PubMed
  2. Wu J, et al. 2022. Nat Commun. 13:676. PubMed
  3. Liu T, et al. 2020. Biochem Biophys Res Commun. 532:385. PubMed
  4. Zhang T, et al. 2022. IUBMB Life. 74:1081. PubMed
  5. Yüce M, et al. 2022. J Cell Biochem. 123:1966. PubMed
  6. Albayrak E, et al. 2022. J Cell Biochem. 123:2009. PubMed
  7. Wang H, et al. 2022. Oxid Med Cell Longev. 2022:3082969. PubMed
  8. Ferreira-Baptista C, et al. 2022. Bioengineering (Basel). 9: . PubMed
  9. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  10. Lin L, et al. 2023. Mol Ther Nucleic Acids. 31:88. PubMed
  11. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  12. Camerlingo R, et al. 2011. Lung Cancer. 72:23. PubMed
  13. Peng K, et al. 2020. Sci Rep. 10:18433. PubMed
  14. Yan H, et al. 2020. Adv Sci (Weinh). 7:1903516. PubMed
  15. Xin Y, et al. 2021. Stem Cell Res Ther. 49:12. PubMed
  16. Lee CW, et al. 2022. J Adv Res. 39:73. PubMed
  17. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  18. Hua J, et al. 2023. Ann Transl Med. 11:62. PubMed
  19. Uzieliene I, et al. 2023. Int J Mol Sci. 24:. PubMed
  20. Pal D, et al. 2023. Nat Commun. 14:1129. PubMed
  21. Che L, et al. 2023. Foods. 12:. PubMed
  22. Wan L, et al. 2023. PeerJ. 11:e15164. PubMed
  23. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
  24. Lu Y, et al. 2023. Sci Rep. 13:8479. PubMed
  25. Hu H, et al. 2023. Front Mol Neurosci. 16:1179175. PubMed
  26. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  27. Yu XX, et al. 2021. Cell Res. 31:886. PubMed
  28. Shi L, et al. 2021. Stem Cell Res Ther. 12:147. PubMed
  29. Li L, et al. 2015. Int J Pharmaceutics. 488: 1-11. PubMed
  30. Liu X, et al. 2020. Exp Ther Med. 1.258333333. PubMed
  31. Radhakrishnan S, et al. 2019. Mol Med Rep. 20:813. PubMed
  32. Guney-Esken G, et al. 2021. Stem Cell Res Ther. 12:287. PubMed
  33. Tu S, et al. 2020. Cellular Signalling. 73:109695. PubMed
  34. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  35. Huang X, et al. 2019. Oxid Med Cell Longev. 2019:1305049. PubMed
  36. Takao T, et al. 2022. STAR Protoc. 3:101786. PubMed
  37. Qin XY, et al. 2020. Cell Death Dis. 0.504166667. PubMed
  38. Hwang Y, et al. 2021. Int J Mol Sci. 22:. PubMed
  39. Dregalla RC, et al. 2021. Stem Cell Res Ther. 12:547. PubMed
  40. Nguyen MAT, et al. 2020. Immunohorizons. 0.465277778. PubMed
  41. Liu Z, et al. 2021. Molecules. 26:. PubMed
  42. Han X, et al. 2020. Int J Oral Sci. 12:10. PubMed
  43. Hanse E, et al. 2017. Oncogene. 10.1038/onc.2017.36. PubMed
  44. Sun W, et al. 2019. Exp Ther Med. 17:2199. PubMed
  45. Albayrak E, et al. 2021. J Cell Physiol. 236:8122. PubMed
  46. Liu Y, et al. 2022. iScience. 25:104405. PubMed
  47. Yan K, et al. 2022. iScience. 25:104822. PubMed
  48. DAgostino S, et al. 2021. Frontiers in Oncology. 10:600980. PubMed
  49. Kinchen J et al. 2018. Cell. 175(2):372-386 . PubMed
  50. Gao P, et al. 2017. Cytotechnology. 69:751. PubMed
  51. Nguyen JT, et al. 2019. iScience. 17:190. PubMed
  52. Yu C, et al. 2020. Sci Rep. 10:14521. PubMed
  53. Duan X, et al. 2022. Cell Biosci. 12:60. PubMed
  54. Fawkner-Corbett D, et al. 2021. STAR Protoc. 2:100890. PubMed
  55. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  56. Yang C et al. 2019. Int J Mol Med. 43(3):1395-1405 . PubMed
  57. Uslu M, et al. 2020. J Cell Physiol. 235:9644. PubMed
  58. Tidu F, et al. 2021. iScience. 24(6):102683. PubMed
  59. Ayhan S, et al. 2021. Journal of Cell Science. 134(6):. PubMed
  60. Cai S, et al. 2022. Cell Biosci. 12:115. PubMed
  61. Noz MP, et al. 2020. Elife. 9:00. PubMed
  62. Zhang Y, et al. 2018. Stem Cells Int. 2018:7159465. PubMed
  63. Zhang Y, et al. 2019. Aging (Albany NY). 11:12641. PubMed
  64. Guney-Esken G, et al. 2021. Methods Mol Biol. 2549:23. PubMed
  65. Keshtkar S, et al. 2021. Stem Cells Int. 8857457:2020. PubMed
  66. Okamura G, et al. 2020. Int J Mol Sci. 22:00. PubMed
  67. Zhang H, et al. 2017. Oncogene. 10.1038/onc.2016.512. PubMed
  68. Sun T, et al. 2019. Haematologica. 105:661. PubMed
  69. Motedayyen H, et al. 2017. BMC Res Notes. . 10.1186/s13104-017-2880-6. PubMed
  70. Narakornsak S, et al. 2017. Acta Histochemica. 10.1016/j.acthis.2017.04.006. PubMed
  71. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  72. Miksiunas R, et al. 2022. Cells. 11:. PubMed
  73. Aomatsu E, et al. 2014. Sci Rep. 4:3652. PubMed
  74. Fawkner-Corbett D, et al. 2021. Cell. 184(3):810-826.e23. PubMed
  75. He Z, et al. 2020. J Exp Clin Cancer Res. 39:140. PubMed
  76. Meng Z, et al. 2013. Mol Cancer Ther. 12:2067. PubMed
  77. He H, et al. 2019. J Cell Mol Med. 23:4139. PubMed
  78. Zhu YP et al. 2018. Cell reports. 24(9):2329-2341 . PubMed
  79. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  80. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  81. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  82. Putra I, et al. 2021. Transl Vis Sci Technol. 10:3. PubMed
  83. Matheni C, et al. 2021. Cell J. 23:145. PubMed
  84. Miksiunas R, et al. 2020. Int J Mol Sci. 21:00. PubMed
  85. Luzuriaga J, et al. 2020. Biomedicines. 8:00. PubMed
  86. Dinh HQ, et al. 2020. Immunity. 53(2):319-334.e6. PubMed
  87. Hong Y, et al. 2020. Aging Cell. 19:e13128. PubMed
  88. Chijimatsu R, et al. 2022. Regen Ther. 21:52. PubMed
  89. Shang W, et al. 2022. Dis Markers. 2022:7286645. PubMed
  90. Khanh VC, et al. 2021. Stem Cells Dev. 30:758. PubMed
  91. Thiel A, et al. 2015. Sci Rep. 5: 17685. PubMed
  92. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
RRID
AB_893438 (BioLegend Cat. No. 328107)
AB_893429 (BioLegend Cat. No. 328108)

Antigen Details

Structure
25-35 kD glycoprotein, Ig superfamily
Distribution

Subset of CD34+ hematopoietic stem cells, subset of fetal thymocytes, subset of fetal liver cells, fibroblast, activated endothelial cells, neurons and some leukemia cell lines

Function
Regulate hematopoiesis and neural cell growth, cell adhesion
Ligand/Receptor
β3 integrin, β2 integrin
Cell Type
Endothelial cells, Fibroblasts, Hematopoietic stem and progenitors, Leukemia, Mesenchymal Stem Cells, Neurons, Thymocytes
Biology Area
Immunology, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. McKenzie JL, et al. 1981. J. Immunol. 126:843.
2. Avalos AM, et al. 2002. Biol. Res. 35:231.
3. Wetzel A, et al. 2004. J. Immunol. 172:3850.

Gene ID
7070 View all products for this Gene ID
UniProt
View information about CD90 on UniProt.org
Go To Top Version: 3    Revision Date: 08.04.2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account